ArticleJCO global oncology2022

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.

Chanchai Charonpongsuntorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.